Close Menu

NEW YORK – Personalis said today that it is engaged in a research collaboration with Sarepta Therapeutics in which it is using its platform to characterize the immune response to certain precision genetic therapeutics.

Financial terms of the deal were not disclosed and Personalis did not name specific drugs or disease areas being studied, but Sarepta describes its pipeline as encompassing a suite of experimental genetic medicines for to treat rare neuromuscular and central nervous system diseases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.